

Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

NEWARK, Calif., May, 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain"), a late-stage biotechnology company developing precision oncology therapeutics, today announced it will be presenting three posters highlighting its oral mouse double minute 2 (MDM2) inhibitor, milademetan, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 3–7, 2022.

Additional presentation details can be found below:

Title: Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan

Abstract Number: 3136

Presenter: Vijaya G. Tirunagaru, Ph.D., Sr. Vice President and Head of Research, Rain Therapeutics, Newark, CA

Poster Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

Poster Number: 128

Date/Time: Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT

Title: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with dedifferentiated liposarcomas

Abstract Number: TPS11589 (Trial in Progress Poster)

Presenter: Mrinal M. Gounder, M.D., Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

Poster Session: Sarcoma

Poster Number: 489b

Date/Time: Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT

Title: MANTRA-2: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors

Abstract Number: TPS3165 (Trial in Progress Poster)

Presenter: Ecaterina Elena Dumbrava, M.D., The University of Texas MD Anderson Cancer Center

Poster Session: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

Poster Number: 149b

Date/Time: Sunday, June 5, 2022, 8:00 – 11:00 a.m. CT

Copies of each poster will be available by visiting the "[Events](#)" section of the Rain website after the conclusion of the presentations and will be archived on the Rain website.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact

Jordyn Temperato

LifeSci Communications

jtemperato@lifescicomms.com

Investor Contact

Bob Yedid

LifeSci Advisors

+1.646.597.6989

bob@lifesciadvisors.com